Liposomal delivery system enhances anti-inflammatory properties of curcumin

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 598-609

  Basnet, Purusotam ^a   Hussain, Haider ^a   Tho, Ingunn ^a   Skalko Basnet, Natasa ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anti inflammatory; Antioxidant; Cancer chemoprevention; Controlled delivery; Curcumin; Drug delivery systems; Liposomes; Nanoparticles; Topical drug delivery; Vaginal therapy

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; ANTIINFLAMMATORY AGENT; CURCUMIN; CURCUMIN I; CURCUMIN II; CURCUMIN III; CURCUMINOID DERIVATIVE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; LIPOSOME; NITRIC OXIDE; PHOSPHOLIPID; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MACROPHAGE; MOUSE; NONHUMAN; PARTICLE SIZE;

EID: 84455208306     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22785     Document Type: Article

References (41)

1. Basnet P, Skalko-Basnet N. 2011. Curcumin: An anti-inflammatroy molecule from a curry spice on the path to cancer treatment. Molecules 16:4567-4598.
2. Zhou H, Beevers CS, Huang S. 2011. The targets of curcumin. Curr Drug Targets 12:332-347.
3. Strimpakos AS, Sharma RA. 2008. Curcumin: Preventative and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10:511-545.
4. Aggarwal BB. 2004. Nuclear factor-κB: The enemy within. Cancer Cell 6:203-208.
5. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS. 2001. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat Res 480-481:243-268.
6. Salh B, Assi K, Templeman V, Parhar K, Owen D, Gomez-Munoz A, Jacobson K. 2003. Curcumin attenuates DNB-induced murine colitis. Am J Physiol 285:G235-G243.
7. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, Talero E, Sanchez-Fidalgo S, Motilva V, de la Lastra CA. 2007. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7:333-342.
8. Kundu JK, Surh YJ. 2010. Nrf2-KeapI signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis. Pharm Res 27:999-1013.
9. US National Institute of Health. Accessed March 25, 2011, at:.
10. Anonymous (NCI, US). 1996. Clinical development plan: Curcumin. J Cell Biochem Suppl 26:72-85.
11. di Cagno M, Styskala J, Hlaváč J, Brandl M, Bauer-Brandl A, Skalko-Basnet N. 2011. Liposomal solubilization of new 3-hydroxy-quinolinone derivatives with promising anticancer activity: A screening method to identify maximum incorporation capacity. J Liposome Res. [Epub ahead of print].
12. Pavelic Z, Skalko-Basnet N, Jalsenjak I. 1999. Liposomes containing drugs for treatment of vaginal infections. Eur J Pharm Sci 8:345-351.
13. Pavelic Z, Skalko-Basnet N, Schubert R. 2004. Liposomal gels for vaginal drug delivery. Methods Enzymol 387:287-299.
14. Pavelic Z, Skalko-Basnet N, Jalsenjak I. 2005. Characterization and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis. Int J Pharm 301:140-148.
15. Pavelic Z, Skalko-Basnet N, Filipovic Grcic J, Martinac A, Jalsenjak I. 2005. Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Control Release 106:34-43.
16. Fichorova RN, Zhou F, Ratnam V, Atanassova V, Jiang S, Strick N, Neurath AR. 2005. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1, 2-benzendicaroxylate in a human in vitro model of vaginal inflammation. Antimicrob Agents Chemother 49:323-335.
17. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420:860-867.
18. Martins CVB, da Silva DL, Neres ATM, Magalhaes TFF, Watanabe GA, Modolo LV, Sabino AA, de Fatima A, de Resende MA. 2009. Curcumin as a promising antifungal of clinical interest. J Antimicrob Chemother 63:337-339.
19. Rasmussen HB, Christensen SB, Kvist LP, Karazmi A. 2000. A simple and efficient separation of curcumins, the antiprotozoal constituents of Curcuma longa. Planta Med 66:396-398.
20. Skalko N, Cajkovac M, Jalsenjak I. 1998. Liposomes with metronidazole for topical use: The choice of preparation method and vehicle. J Liposome Res 8:283-293.
21. Basnet P, Matsuno T, Neidlein R. 1997. Potent free radical scavenging activity of propol isolated from propolis. Z Naturforsch 52:828-833.
22. Beauchamp C, Fridovich I. 1971. Superoxide dismutase: Improved assay and an assay applicable to acrylamide gels. Anal Biochem 44:276-287.
23. Bansal SS, Vadhanam MV, Gupta RC. 2011. Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm Res 28:1121-1130.
24. Zhang F, Koh GY, Jeansonne DP, Hollingsworth J, Russo PS, Vicente G, Stout RW, Liu Z. 2011. A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity. J Pharm Sci 100:2778-2789.
25. Shaik J, Ankola DD, Beniwal V, Singh D, Ravi Kumar MNV. 2009. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37:223-230.
26. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. 2007. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicle for the solubilization, stabilization and controlled delivery of curcumin. J Biomed Mater Res A 86:300-310.
27. Bisht S, Feldman G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A. 2007. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J Nanobiotech 5:1-18.
28. Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert RO, Martin F, Mueller-Goymann C. 2010. Phospholipids and lipid-based formulations for oral delivery. Pharm Res 27:1469-1486.
29. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. 2007. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60:171-177.
30. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. 2007. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 330:155-163.
31. Tiyaboonchai W, Tungpradit W, Plianbangchang P. 2007. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 337:299-306.
32. Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. 2009. Evaluation of an oral carrier system in rats: Bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem 57:9141-9146.
33. Li L, Braiteh FS, Kurzrock R. 2005. Liposome-encapsulated curcumin, in vitro and in vivo effects on proliferation, apoptosis, signaling and angiogenesis. Cancer 104:1322-1331.
34. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. 2008. Evaluation of nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 32:1119-1123.
35. Kunwar A, Barik A, Pandey R, Priyadarsini KI. 2006. Transport of liposomal and albumin loaded curcumin to living cells: An absorption and fluorescence spectroscopic study. Biochim Biophys Acta 1760:1513-1520.
36. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
37. Srinivasan M, Prasad NR, Menon VP. 2006. Protective effect of curcumin on γ-radiation induced DNA damage and lipid peroxidation in cultured human lymphocytes. Mutat Res 611:96-103.
38. Khan N, Afaq F, Mukhtar H. 2008. Cancer chemoprevention through dietary antioxidants: Progress and promise. Antioxid Redox Signal 10:475-510.
39. Biesalski HK. 2007. Polyphenols and inflammation: Basic interactions. Curr Opin Clin Nutr Metab Care 10:724-728.
40. Finkel T, Holbrook NJ. 2000. Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247.
41. Surh YJ, Na HK. 2008. NF-κB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr 2:313-317.